Literature DB >> 2167671

Expression of the erythropoietin receptor on a human myeloma cell line.

Y Okuno1, T Takahashi, A Suzuki, S Ichiba, K Nakamura, K Hitomi, R Sasaki, H Imura.   

Abstract

We demonstrated the expression of the erythropoietin (EPO) receptor by a human myeloma cell line (MM-S1) which was established in our laboratory. EPO dose-dependently stimulated the proliferation of MM-S1 cells. Binding of radioiodinated EPO (125I-Epo) to MM-S1 cells was competitively inhibited by unlabeled EPO, but not by other recombinant cytokines. Specific binding of 125I-Epo to MM-S1 cells was saturable, and the Scatchard analysis revealed 330 EPO binding sites per cell with a Kd of 0.56 nmol/L. Bound EPO was internalized by MM-S1 cells during incubation at 37 degrees C. This is the first report describing the expression of the EPO receptor by human cells other than those of the erythroid lineage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167671     DOI: 10.1016/0006-291x(90)90510-t

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Does erythropoietin accelerate malignant transformation in multiple myeloma?

Authors:  A Olujohungbe; S Handa; J Holmes
Journal:  Postgrad Med J       Date:  1997-03       Impact factor: 2.401

2.  Pleiotrophic actions of erythropoietin.

Authors:  Laurie Feldman; Arthur J Sytkowski
Journal:  Environ Health Prev Med       Date:  2003-01       Impact factor: 3.674

3.  Unregulated expression of the erythropoietin receptor gene caused by insertion of spleen focus-forming virus long terminal repeat in a murine erythroleukemia cell line.

Authors:  M Hino; A Tojo; Y Misawa; H Morii; F Takaku; M Shibuya
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

Review 4.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

5.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

Authors:  F Silvestris; A Romito; P Fanelli; A Vacca; F Dammacco
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.